The approval is supported by data from the Phase III NRG-GY018/ KEYNOTE-868 trial, in which the regimen reduced the risk of disease progression or death by 40% in patients whose cancer was mismatch repair proficient and by 70% in patients whose cancer was mismatch repair deficient, when compared to placebo with carboplatin and paclitaxel followed by placebo alone
Other ECM-derived peptides In addition to P-15 and RGD, other ECM-derived peptides are currently being developed for potential applications in amplifying the bone healing response
References: [1] Seiwerth, S., Milavic, M., Brcic, L., & Sikiric, P
Similarly, those using peptides for muscle growth may experience mood benefits from improved testosterone levels, better sleep, and the well-documented antidepressant effects of regular resistance training facilitated by enhanced recovery